Beijing Tri-prime Genetic Engineering Co., Ltd.

Industry: Biotechnology

Investee: "α1b Genetic Engineering Interferon", result of 863 Hi-tech Research and Development Program, Beijing Institute of Virology under Chinese Science Academy of Preventive Medicine.

Investment Initiator: China KZ High Technology Co., Ltd., Beijing Institute of Virology under Chinese Science Academy of Preventive Medicine, and Beijing Hi-Tech transfer Service Center

Follow-up Investment: Many organizations, such as Shenzhen Donar Industrial Co., Ltd., Zhejian Sheng Da Pharmaceutical Co., Ltd., 21st Century VC Investment Co., Ltd., Qingdao Hivew Property Co., Ltd. invested successively from 1998 to 2001.

Current Conditions of the Enterprise: It is a domestic well-known modern biomedidine enterprise, enterprise, mainly engaged in the research, development, production and distribution of medical biotechnology of medical biotechnology products including genetic engineering medicine, genetic engineering bacterin and bacterin and diagnostic reagents. The company with strong power of research and development was officially authorized by the National Ministry of personnel to establish the postdoctoral scientific research center. The company has built first-class factories in Bejing Daxing Industrial Development Zone,which were the first to receive national GMP certification.It's main genetic engineering product "Hapgen" is a State Class-A medicine, which is effective in the treament of many kinds of viruses and malignant tumors. At present, Phase Ⅱproject of Tri-Prime Gene-The Tri-Prime Genetic Garden has broken ground, which going to be the world-level science and business center for the development, production and commercialization of genetic engineering products.

web site: www.triprime.com